Method for determining a therapeutic approach for the treatment of age-related macular degeneration (amd)
AssigneeArcticDx Inc.
InventorsBrent Zanke, Carl Awh
Life of this patent
Estimating the term…
Abstract
Disclosed is a method for determining a supplement regime for a subject diagnosed with age-related macular degeneration (AMD). The method involves determining the subject's risk of developing advanced AMD based on their genetic profile for the complement factor H gene and the ARMS2 gene and administering a supplement containing antioxidants and/or zinc based on their risk of developing advanced AMD.
Claims18
A method of determining a supplement regime for a subject diagnosed with age-related macular degeneration (AMD) comprising:
- (a) determining the subject's risk of developing advanced AMD in a sample from said subject based on their genetic profile for the complement factor H gene and the Age-Related Maculopathy Suspectibility 2 (ARMS2) gene and
- (b) administering a supplement based on said determining step, wherein when the subject has zero risk alleles for CFH and 1 risk allele for ARMS the supplement is zinc/copper alone;
- wherein when the subject has 1 risk allele for CFH and zero risk alleles for ARMS2 the supplement is antioxidants alone;
- wherein when the subject has 0 risk alleles for CFH and two risk alleles for ARMS2 the supplement is zinc/copper alone;
- wherein when the subject has one risk allele for CFH and one risk allele for ARMS2 the supplement is both zinc/copper and antioxidants, wherein when the subject has 2 risk alleles for CFH and zero risk alleles for ARMS2 the supplement is antioxidants alone, wherein when the subject has one risk allele for the CFH gene and two risk alleles at the ARMS2 locus the supplement is zinc alone.
The method of claim 10, wherein the subject is considered at low risk of developing advanced AMD when the subject is homozygous for the C allele at rs3766405 (position 27 of SEQ ID NO:
- 1) and is homozygous for the T allele at rs412852 (position 27 of SEQ ID NO:
- 2), heterozygous for the C allele at rs3766405 (position 27 of SEQ ID NO:
- 1) and is homozygous for the C allele at rs412852 (position 27 of SEQ ID NO:
- 2), heterozygous for the C allele at rs3766405 (position 27 of SEQ ID NO:
- 1) and is homozygous for the T allele at rs412852 (position 27 of SEQ ID NO:
- 2), homozygous for the T allele at rs3766405 (position 27 of SEQ ID NO:
- 1) and is homozygous for the C allele at rs412852 (position 27 of SEQ ID NO:
- 2), homozygous for the T allele at rs3766405 (position 27 of SEQ ID NO:
- 1) and is heterozygous for the C allele at rs412852 (position 27 of SEQ ID NO:
- 2) or homozygous for the T allele at rs3766405 (position 27 of SEQ ID NO:
- 1) and is homozygous for the T allele at rs412852 (position 27 of SEQ ID NO:
- 2).
Dependencies are inferred from the claim text.